Trial reportClinical cardiology2018
Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.
Trial report in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00475852 (Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.Clinical cardiology · 2018Trial
- Impact of rate-pressure product correction of myocardial blood flow on the prognostic relevance in patients with heart failure.European heart journal. Cardiovascular Imaging · 2026Article
- Early Cardiac Workload and Long-Term Prognosis After Intracerebral Hemorrhage: Insights from a Large Multicenter Cohort.Reviews in cardiovascular medicine · 2026Article
- Pre-Hospital Rate-Pressure Product Is Not Positively Associated with Hematoma Expansion or Initial Hematoma Volume in Spontaneous Intracranial Hemorrhage.Neurology international · 2026Article
- Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk.Frontiers in neurology · 2025Article
- Article
- Prognostic Value of Nighttime Double Product in Nondialysis Chronic Kidney Disease With Hypertension.Journal of the American Heart Association · 2023Article
- Blood pressure, heart rate, or the Rate Pressure Product: what is the best predictor of clinical outcome?European heart journal open · 2022Article
- Admission rate-pressure product as an early predictor for in-hospital mortality after aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2022Article
- Predictive Value of Heart Rate and Blood Pressure on the Prognosis of Postural Tachycardia Syndrome in Children.Frontiers in pediatrics · 2022Article
- Towards optimization of cardiovascular stability in neonates with hypertrophic cardiomyopathy: uniqueness of the neonatal cardiovascular system.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Vasopressin in neonatal hypertrophic cardiomyopathy: do perceived benefits translate to clinical outcome?Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Relationship of anthropometric indices with rate pressure product, pulse pressure and mean arterial pressure among secondary adolescents of 12-17 years.BMC research notes · 2021Article
- Association of double product and pulse pressure with cardiovascular and all-cause mortality in the LURIC study.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Cardiovascular rate pressure product is associated with NfL in older adults at risk for AD.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundHeart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear. HYPOTHESIS: RPP and its components are associated with HFpEF outcomes.
methodsWe performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.
resultsAfter multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P < 0.05). Baseline SBP was associated with 180-day mortality (HR: 0.88 per 10-mm Hg, P = 0.028). Though change in RPP was associated with 30-day mortality/HF hospitalization, the RPP baseline variable did not provide additional associative information with regard to outcomes when compared with assessment of baseline heart rate and SBP variables alone.
conclusionsAn increase in heart rate and SBP from baseline to discharge was associated with increased 30-day mortality/HF hospitalization in HFpEF patients with acute exacerbation. These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.